International Stem Cell Corporation

Total Valuation

International Stem Cell Corporation carries a market capitalization of 2.28M, placing it among publicly traded companies globally. Its enterprise value stands at 3.85M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

International Stem Cell Corporation currently has 8.00M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.16, and the price-to-book ratio stands at -0.35.

Enterprise Valuation

On an enterprise value basis, International Stem Cell Corporation trades at an EV/EBITDA multiple of 12.25 and an EV/FCF ratio of 6.88. The EV/Sales ratio of 0.40 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 39.90 provides insight into valuation relative to core operating earnings.

Financial Position

International Stem Cell Corporation maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -81.72, indicating conservative leverage, while an interest coverage ratio of -1.94 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

International Stem Cell Corporation's stock has gained approximately 90% over the past 52 weeks. The 50-day moving average sits at 0.36, while the 200-day moving average is 0.22.

Income Statement

Over the trailing twelve months, International Stem Cell Corporation generated 9.51M in revenue and converted that into -582,000.00 in net income, yielding earnings per share of -0.07. EBITDA reached -273,000.00, while operating income came in at -444,000.00.

Balance Sheet

International Stem Cell Corporation holds 1.09M in cash and equivalents against 3.46M in total debt, resulting in a net debt position of 2.17M. Total book value stands at -4.23M, with working capital of -1.06M providing operational flexibility.

Cash Flow

International Stem Cell Corporation produced 369,000.00 in operating cash flow over the past twelve months. After subtracting -50,000.00 in capital expenditures, free cash flow totaled 319,000.00 - equivalent to 0.04 per share.

Margins

International Stem Cell Corporation operates with a gross margin of 54.96, reflecting its pricing power and cost economics. The operating margin of -4.67 and net profit margin of -6.12 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

International Stem Cell Corporation's most recent stock split took place on July 29, 2015 with a 150:1 split ratio.

Scores

International Stem Cell Corporation posts an Altman Z-Score of -32.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.